Distribution Agreement for Oncology Assays

By Labmedica staff writers
Posted on 22 Apr 2002

A global distribution agreement for oncology-related serum assays in microtiter plate ELISA format has been announced by Dako A/S (Glostrup, Denmark) and Bayer Diagnostics (Tarrytown, NY, USA). The assays are designed to aid oncologists in the confirmation, monitoring, staging, screening, and prognosis of cancer.

Under the terms of the agreement, which is for five years, Bayer Diagnostics Oncogene Science Group is responsible for the manufacture and technical support of the product line, while Dako is responsible for worldwide sales, marketing, and customer support.
The assays include proprietary serum tests for the Her-2/neu oncoprotein, epidermal growth factor receptor (EGFr), urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and an assay that detects the complexes between uPA and PAI-1. Also included are separate tests for measuring the total and complexed forms of prostate-specific antigen (PSA) to aid in the detection of prostate cancer.

"This agreement puts an entirely new set of unique and important oncology research and disease management products in the hands of Dako's sales force,” said Jes Ostergaard, CEO of Dako, "and it underscores our commitment to bridging the diagnostic testing of oncology patients with their treatments.”

Related Links:
Bayer
Dako